Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) insider Michael Geffner sold 3,261 shares of the business’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $28.90, for a total value of $94,242.90. Following the transaction, the insider now owns 141,616 shares in the company, valued at approximately $4,092,702.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Immunovant Trading Down 2.1 %
Shares of Immunovant stock opened at $27.17 on Friday. Immunovant, Inc. has a 1 year low of $15.90 and a 1 year high of $45.58. The firm’s 50-day moving average is $32.10 and its 200 day moving average is $35.79.
Immunovant (NASDAQ:IMVT – Get Free Report) last issued its earnings results on Monday, February 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. Equities analysts expect that Immunovant, Inc. will post -1.7 EPS for the current year.
Institutional Trading of Immunovant
Wall Street Analyst Weigh In
A number of equities analysts recently commented on IMVT shares. JPMorgan Chase & Co. initiated coverage on Immunovant in a report on Tuesday, February 20th. They set an “overweight” rating and a $51.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunovant in a research note on Friday, January 12th. Truist Financial reissued a “buy” rating and issued a $48.00 price target on shares of Immunovant in a research note on Monday, March 25th. Wolfe Research began coverage on Immunovant in a research note on Thursday, February 15th. They issued an “outperform” rating and a $55.00 target price for the company. Finally, The Goldman Sachs Group initiated coverage on Immunovant in a research report on Wednesday, March 13th. They set a “buy” rating and a $50.00 price target on the stock. Seventeen research analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunovant presently has an average rating of “Buy” and an average price target of $48.00.
Check Out Our Latest Stock Analysis on Immunovant
Immunovant Company Profile
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
Recommended Stories
- Five stocks we like better than Immunovant
- Most active stocks: Dollar volume vs share volume
- MarketBeat Week in Review – 4/22 – 4/26
- Investing in Travel Stocks Benefits
- 3 Stocks Leading the U.S. Agriculture Comeback
- What Are the FAANG Stocks and Are They Good Investments?
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.